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http://dx.doi.org/10.1016/j.jmii.2013Purpose: Candidemia is an important issue of nosocomial bloodstream infections, and is asso-
ciated with a high mortality rate. However, little information is available before final species
identification, which takes days after the episode of candidemia. This study tried to determine
whether time to positivity (TTP) for yeast helps in predicting the species of candidemia.
Methods: A retrospective cohort study was conducted in Taiwan, which included 434 episodes
of nonduplicated candidemia during the period between 2006 and 2009. The demographic
features, clinical characteristics, TTP for yeast, and acute illness scores were included for
analysis.
Results: The mean age of patients with candidemia was 70.4  15.2 years, and the 30-day
crude mortality rate was 48.2%. Forty-five percent of patients suffered from shock status with
a mean Acute Physiological and Chronic Health Evaluation II score of 27.0  8.7 and a mean
Sequential Organ Failure Assessment score of 9.7  4.5, whereas 50% were admitted to the
intensive care units. Candida albicans was still the most commonly identified pathogen
(58.1%), followed by C. tropicalis (14.7%), C. parapsilosis (13.1%), and C. glabrata (8.3%). Re-
sults of multivariate logistic regression showed that TTP for yeast within 48 hours would morefectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Number 201, Section 2,
v.tw (F.-D. Wang).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
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426 L.-Y. Chen et al.favor C. tropicalis (p Z 0.044), and less favor C. glabrata (p Z 0.025) and C. parapsilosis
(p < 0.001). Patients with parenteral nutrition usage were more frequently associated with
a TTP for yeast within 48 hours, whereas those with previous exposure to an antifungal agent
had a longer TTP for yeast.
Conclusion: The TTP for yeast might provide a hint of the responsible Candida species before
final identification among critical patients with candidemia. The association between anti-
fungal agents and TTP would need more evidence for elucidation.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Invasive fungal infections in hospitalized patients are
associated with significant morbidity and mortality.1 The
mortality rate associated with invasive candidiasis was as
high as 40e50%.2e4 Candida species are the most common
cause of invasive fungal infections, accounting for approx-
imately 15% of total hospital-acquired infections and more
than 72% of nosocomial fungal infections.1,5 Moreover,
candidemia has become the fourth most common cause of
nosocomial bloodstream infections in the United States and
in much of the developed world.1,2,6
The time to positivity (TTP) of blood culture in patients
with candidemia was less discussed in the clinical field,
although it is generally agreed that the mean time for
detection of Candida species growth varies among species.
Most species were identified positive for yeasts within 48
hours in an in vitro blood-culture system, but there was a
delay in final species identification.7,8 Thus, the TTP for
yeast might be a simple indicator for predicting the invaded
Candida species, and would help clinicians to make a de-
cision on the antifungal treatment required. A recent study
by Fernandez et al reported that Candida glabrata would
take long TTP for yeast by the BacT/ALERT system, which
delayed appropriate antifungal therapy.8 Another study by
Ben-Ami et al reported that the TTP for yeast could be a
marker for catheter-related candidemia.9
However, the mortality and associated clinical presen-
tation among patients with candidemia were no fully
explored in the previous two studies. To clarify the impor-
tance of TTP for yeast, a retrospective cohort study was
conducted to evaluate its impact on mortality, final species
identifications, and associated risk factors in a tertiary
medical center in Taiwan.Materials and methods
Patient identification and data collection
This retrospective cohort study examined all patients with
a positive blood culture for yeasts (confirmed by microbi-
ological laboratory testing) at a 2900-bed tertiary medical
center during the period between January 1, 2006 and
December 31, 2009. The blood cultures were collected in
paired aerobic and anaerobic bottles by standard sterile
procedures via the peripheral vessels. Every episode was
identified as true candidemia by reviewing the medicalrecords of those patients with concomitant symptoms or
signs of systemic inflammatory response syndrome.10 De-
mographic characteristics and clinical presentation among
patients as well as acute illness severity scores, such as the
Acute Physiological and Chronic Health Evaluation II
(APACHE II) and Sequential Organ Failure Assessment (SOFA)
scores, were collected for analysis.11,12 The TTP for yeast,
final species identification, and the susceptibility tests re-
sults were also evaluated. This study was approved by the
Institutional Review Board of the hospital.
Patients were excluded from participating in the study if
they were younger than 16 years, were identified as having
two or more Candida species at the same time, or had
another episode diagnosed within 30 days. Patients with
two episodes of candidemia diagnosed 30 days apart were
considered as having acquired another infectious episode
unless a failed primary focus eradication was identified.13
Microbiological identification
Pathogens were initially isolated from aerobic blood cul-
tures using the BacT/ALERT 3D system (bioMe´rieux, Inc.,
Marcy-l’E´toile, France) during the study period. The labo-
ratory receipt time and the TTP for yeast were recorded
manually by the technicians. The data were reported online
in the hospital computerizing system and medical staff had
open access to these data. Species were identified by
standard biochemical testing using an ATB ID 32C kit (bio-
Me´rieux, Hazelwood, MO, USA) and the VITEK 2 system with
ID-YST Card (bioMe´rieux VITEK, Hazelwood, MO, USA). The
susceptibility results were interpreted based on the criteria
specified by the Clinical and Laboratory Standards
Institute.14
Definition
The TTP for yeast was defined by the manually recorded
time to growth detection for yeast minus the laboratory
receipt time accessible on website by physicians. Because
most blood cultures reported positive for yeasts within 48
hours in clinical experience, this duration was chosen as the
cutoff value of TTP. The underlying comorbidities were
identified by the medical records with clear documenta-
tion. Catheter-related infection was defined by semi-
quantitative tip culture of indwelling catheter with growth
15 colonies that are identical to the species identified
from the peripheral blood culture. Chronic renal insuffi-
ciency was identified based on serum creatinine levels
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clearance < 30 mL/minute/1.73 m2 for >6 months, and
end-stage renal disease was defined as serum creatinine
levels >3.0 mg/dL or estimated serum creatinine
clearance < 10 mL/minute/1.73 m2 for over 6 months.
Immunosuppressive therapy was defined by the use of im-
munosuppressants or corticosteroids in equivalent dosage
to prednisolone (20 mg/day or more) for at least 3 days.
Candidemia patients were defined neutropenic if their ab-
solute neutrophil count was <1000 cells/mm3 and were
defined thrombocytopenic if their platelet count was
<100,000 cells/mm3. Peripheral parenteral nutrition only
included those with the administration of lipid-containing
formulation. Colonization was defined as positive growth
of yeast from at least one surveillance site.13,15Statistical analysis
The Chi-square test or Fisher exact test was used for cat-
egorical comparisons of data and differences in continuous
variables were analyzed by the independent Student t test.
A p value < 0.05 was considered statistically significant.
Significant predictors in the univariate analysis with a p
value < 0.2 were included for further evaluation. A logistic
regression model was used to identify the most important
risk factors. All analyses were performed using the Statis-
tical Package for the Social Sciences for Windows (version
17.0; SPSS, Inc. Chicago, IL, USA).Results
A total of 485 episodes of candidemia were collected during
the study period. Fifty-one episodes were excluded due to
double species disclosed in the same event or incomplete
clinical data collection. Finally, 434 episodes in 410 pa-
tients were included for analysis. The mean age of patients
with candidemia was 70.4  15.2 years, and 291 (67.1%)
were male. The overall 30-day crude mortality was 48.2%.
Forty-five percent of the patients suffered from shock
status, and 50% of them were admitted in the intensive care
unit. The mean APACHE II score was 27.0  8.7, and the
mean SOFA score was 9.7  4.5 among patients with can-
didemia. C. albicans is the most common pathogen identi-
fied during this study (252 episodes, 58.1%, TTP 58.4  18.2
hours), followed by C. tropicalis (64, 14.7%, TTP
50.6  13.9 hours), C. parapsilosis(57, 13.1%, TTP
71.3  26.9 hours), and C. glabrata(36, 8.3%, TTP
90.7  36.5 hours). Overall demographic and clinical
characteristics, and results of univariate analysis are pre-
sented in Table 1. All patients had received broad-spectrum
antibacterial agents at least 3 days before the antifungal
therapy and thus the usage of antibacterial agents was not
included for further analysis.
In multivariate logistical regression analysis, the anti-
fungal agent exposure in previous 14 days, the Candida
species, comorbidities of diabetic mellitus, use of me-
chanical ventilation, and total usage of parenteral nutrition
showed significant difference after adjustment by age, sex,
and APACHE II score (Table 2). An interaction term between
APACHE II score and use of mechanical ventilation wascreated for further regression analysis, and the effect of
ventilation factor weaned after this adjustment.Discussion
The TTP for yeast showed major difference between spe-
cies on final identification. As reported here, C. tropicalis
was the most frequently identified yeast within 48 hours,
whereas C. glabrata and C. parapsilosis were more
commonly detected over 48 hours, which was similar to
previous studies (Table 2).8,9,13,16 Inevitably, the TTP for
yeast would be closely related to the natural growth speed
of each Candida species by previous results, and it might
provide a clue on species prediction in candidemia.17,18
There is a marked difference between species distribution
within or over 48 hours, and this might aid a clinician to
decide whether to keep fluconazole as the first-line ther-
apeutic agent or shift to other antifungal agents in general
practice. For patients with candidemia of TTP over 48
hours, with limited clinical improvement after fluconazole
administration, and high prevalence of resistant pathogens,
echinocandin would be a reasonable option to cope with
candidemia.19e22
Usage of parenteral nutrition was more frequently
associated with a TTP for yeast within 48 hours. Parenteral
nutrition was long recognized as an important risk factor for
invasive candidiasis,23 and lipid emulsion in parenteral
nutrition was recently recognized as a risk factor for biofilm
formation and catheter-related Candida infection.24 As
presented in our study, total use of parenteral nutrition
containing lipid formulation might be an enrichment factor
for Candida growth and shortened the TTP for yeast as
presented by Swindell et al.24 Moreover, Ben-Ami et al also
reported that shortened TTP for yeast might be an early
predictor for catheter-related candidemia.9 We had eval-
uated whether there would be any interaction between
nontunneled central venous catheter usage and the
Candida species, but no such interaction was found by
statistical analysis. We believed that the use of parenteral
nutrition would be an independent factor for shortening
TTP for yeast among patients with candidemia.
Previous exposure to antifungal agents 14 days before
candidemia was associated with a longer TTP for yeast. One
possible explanation is that antifungal agent administra-
tion, either on purpose of prophylaxis or pre-emptive
treatment, would suppress the most susceptible species,
such as C. albicans, and would increase the identification of
other resistant Candida strains or species.25 Another
possible explanation is that decreased colony counts on
blood culture sampling due to antifungal agent adminis-
tration might also lengthen the TTP for yeast. However, the
relationship between antifungal agents and TTP still needs
more evidence for further elucidation.
Several limitations were encountered in our study. First,
the definition of TTP for yeast used here was different from
those of previous reports by Ben-Ami et al, Fernandez et al,
and Horvath et al that defined TTP using an automatic
machine.8,9,17 A major reason for this study design is that
the TTP for yeast defined here had open access for most
clinicians in daily practice, rather than that defined by
automatic machine, which is only assessed by specialized
Table 1 Demographics and clinical characteristics of patients with candidemia and results of univariate analysis
Variable Overall (n Z 434) TTP for yeast within
48 hours (n Z 229)
TTP for yeast over
48 hours (n Z 205)
p
Hours to yeasts 60.6  22.2 44.8  5.6 81.1  21.6 <0.001
Age (years) 70.4  15.2 66.6  16.2 70.5  15.0 0.009
Male sex 291 (67.1) 151 (65.9) 140 (68.3) 0.602
Onset in ICUs 150 (34.6) 66 (28.8) 84 (41.0) 0.008
Precandidemia LOS (days) 35.6  35.3 45.2  102.2 33.8  29.8 0.091
LOS (days) 65.3  60.3 83.1  143.9 71.3  59.0 0.273
30-day mortality 209 (48.2) 108 (47.2) 101 (49.3) 0.661
APACHE II score 27.0  8.7 23.7  8.3 25.6  9.2 0.020
SOFA score 9.7  4.5 6.3  4.6 7.3  4.9 0.043
Underlying comorbidity
CAD 73 (16.8) 33 (14.4) 40 (19.5) 0.156
CHF 58 (13.4) 24 (10.5) 34 (16.6) 0.062
CVA 88 (20.3) 34 (14.8) 54 (26.3) 0.003
COPD 46 (10.6) 20 (8.7) 26 (12.7) 0.182
CRI 166 (38.2) 70 (30.6) 96 (46.8) 0.001
DM 132 (30.4) 51 (22.3) 81 (39.5) <0.001
Liver cirrhosis 23 (5.3) 16 (7.0) 7 (3.4) 0.097
Pancreatitis 33 (7.6) 23 (10.0) 10 (4.9) 0.043
Collagen vascular disease 15 (3.5) 4 (1.7) 11 (5.4) 0.039
Conditions within previous 30 days
ICU admission 223 (51.4) 108 (47.2) 115 (56.1) 0.063
Surgery 140 (32.3) 66 (28.8) 74 (36.1) 0.105
Immunosuppressive therapy 66 (15.2) 26 (11.4) 40 (19.5) 0.018
Thrombocytopenia 222 (51.3) 127 (55.7) 95 (46.3) 0.052
Procedures
Hemodialysis 74 (17.1) 30 (13.1) 44 (21.5) 0.021
NTCVC 285 (65.8) 150 (65.5) 135 (66.2) 0.883
CVC removal 206 (72.5) 113 (76.9) 93 (67.9) 0.090
Mechanical ventilation 180 (41.5) 78 (34.1) 102 (49.8) 0.001
Arterial line 124 (28.6) 57 (24.6) 67 (32.7) 0.073
Parenteral nutrition 214 (49.3) 137 (59.8) 77 (37.6) <0.001
Urinary catheters 231 (53.2) 108 (47.2) 123 (60.0) 0.007
Candida species <0.001
C. albicans 252 (58.1) 144 (62.9) 108 (52.7)
C. tropicalis 64 (14.7) 50 (21.8) 14 (6.8)
C. parapsilosis 57 (13.1) 16 (7.0) 41 (20.0)
C. glabrata 36 (8.3) 8 (3.5) 28 (13.7)
Fluconazole susceptibilitya 355 (87.2) 201 (92.2) 154 (81.5) 0.002
Catheter-related candidemia 181 (41.8) 110 (48.2) 71 (34.6) 0.004
Antifungal agent exposure in
previous 14 days
44 (10.2) 8 (3.5) 36 (17.6) <0.001
Concurrent bacteremia 69 (15.9) 30 (13.1) 39 (19.0) 0.092
a Fluconazole susceptibility was available among 407 strains.
Data were n (%) or mean  SD unless otherwise indicated.
APACHE II Z Acute Physiological and Chronic Health Evaluation II; CAD Z coronary arterial disease; CHF Z congestive heart failure;
CRI Z chronic renal insufficiency; COPD Z chronic obstructive pulmonary disease; CVA Z cerebrovascular accident; CVC Z central
venous catheter; DM Z diabetes mellitus; ICU Z intensive care unit; LOS Z length of hospital stay; NTCVC Z nontunneled central
venous catheter; SD Z standard deviation; SOFA Z Sequential Organ Failure Assessment; TTP Z time to positivity for yeasts.
428 L.-Y. Chen et al.technicians or microbiologists. Therefore, the TTP reported
in our study was much longer than that reported in previous
studies. However, we believe that this definition of TTP for
yeast might be beneficial for most clinicians in clinical
practice. Second, there might be a time lag between the
real time of yeast detection by machine and the recorded
time for positive finding by a technician due to the manual
processing procedure on sequential cultures. Third, in thisretrospective study, it was difficult to adjust the blood
volume sampled in each episode, which might influent the
inoculation amount in the culture bottle. Finally, the dis-
tribution of C. parapsilosis and C. glabrata was relatively
lower than the other Candida species, and this might cause
some bias on statistical analysis. Further prospective study
to elucidate the role of TTP might be needed in the clinical
field.
Table 2 Associated factors for time to positivity for yeast
within 48 hours by multivariate analysis adjusted by age,
sex, and APACHE II score
Variable Odds ratio (95%
confidence interval)
p
Antifungal agent
exposure in
previous 14 days
0.119 (0.032e0.434) 0.001
Candida speciesa
C. tropicalis 2.497 (1.025e4.415) 0.044
C. glabrata 0.269 (0.086e0.845) 0.025
C. parapsilosis 0.122 (0.046e0.324) <0.001
Mechanical ventilation 0.464 (0.227e0.950) 0.036
Parenteral nutrition 3.514 (1.892e6.527) <0.001
a C. albicans was taken as the reference category for com-
parison between species.
Time to positivity for yeast over 48 hours was taken as refer-
ence group.
Time to positivity for yeast in candidemia 429The TTP for yeast might be a hint towards species pre-
diction before final species identification among patients
with candidemia. Use of parenteral nutrition was associ-
ated with TTP for yeast within 48 hours, whereas previous
exposure to antifungal agents seemed to prolong the TTP
for yeast detection among patients with candidemia.
However, the association between antifungal agents and
TTP would need more evidence for further elucidation.Conflicts of interest
The authors declare that they have no financial or non-
financial conflicts of interest related to the subject matter
or materials discussed in the manuscript.Acknowledgments
We thank the infection control nurses in the Department of
Infection Control, Taipei Veterans General Hospital, for
data collection and candidemia identification during the
study period. This work was supported by a grant from the
Taipei Veterans General Hospital (Grant No.
100DHA0100015).References
1. Pappas PG, Kauffman CA, Andes D, Benjamin Jr DK,
Calandra TF, Edwards Jr JE, et al. Clinical practice guidelines
for the management of candidiasis: 2009 update by the In-
fectious Diseases Society of America. Clin Infect Dis 2009;48:
503e35.
2. Chen LY, Liao SY, Kuo SC, Chen SJ, Chen YY, Wang FD, et al.
Changes in the incidence of candidaemia during 2000e2008 in
a tertiary medical centre in northern Taiwan. J Hosp Infect
2011;78:50e3.
3. Chen YC, Chang SC, Sun CC, Yang LS, Hsieh WC, Luh KT. Secular
trends in the epidemiology of nosocomial fungal infections at a
teaching hospital in Taiwan, 1981 to 1993. Infect Control Hosp
Epidemiol 1997;18:369e75.4. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J,
Messer S, et al. Attributable mortality of nosocomial candide-
mia, revisited. Clin Infect Dis 2003;37:1172e7.
5. Tsai CC, Wang CC, Kuo HY, Chiang DH, Lin ML, Liu CY, et al.
Adult candidemia at a medical center in northern Taiwan: a
retrospective study. J Microbiol Immunol Infect 2008;41:
414e21.
6. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP,
Edmond MB. Nosocomial bloodstream infections in US hospi-
tals: analysis of 24,179 cases from a prospective nationwide
surveillance study. Clin Infect Dis 2004;39:309e17.
7. Bouza E, Sousa D, Mun˜oz P, Rodrı´guez-Cre´ixems M, Fron C,
Lechuz JG. Bloodstream infections: a trial of the impact of
different methods of reporting positive blood culture results.
Clin Infect Dis 2004;39:1161e9.
8. Fernandez J, Erstad BL, Petty W, Nix DE. Time to positive
culture and identification for Candida blood stream infections.
Diagn Microbiol Infect Dis 2009;64:402e7.
9. Ben-Ami R, Weinberger M, Orni-Wasserlauff R, Schwartz D,
Itzhaki A, Lazarovitch T, et al. Time to blood culture positivity
as a marker for catheter-related candidemia. J Clin Microbiol
2008;46:2222e6.
10. Bone RC, Sprung CL, Sibbald WJ. Definitions for sepsis and
organ failure. Crit Care Med 1992;20:724e6.
11. Vincent JL, Ferreira F, Moreno R. Scoring systems for assessing
organ dysfunction and survival. Crit Care Clin 2000;16:353e66.
12. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a
severity of disease classification system. Crit Care Med 1985;
13:818e29.
13. Chen LY, Kuo SC, Wu HS, Yang SP, Chan YJ, Chen LK, et al.
Associated clinical characteristics of patients with candidemia
among different Candida species. J Microbiol Immunol Infect
2013;46:463e8.
14. Clinical and Laboratory Standards Institute. Minutes of the
subcommittee on antifungal susceptibility testing meeting.
Atlanta: Clinical and Laboratory Standards Institute; 2010.
15. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F,
et al. Defining opportunistic invasive fungal infections in
immunocompromised patients with cancer and hematopoietic
stem cell transplants: an international consensus. Clin Infect
Dis 2002;34:7e14.
16. Huang L, Zhang YY, Sun LY. Time to positivity of blood culture
can predict different Candida species instead of pathogen
concentration in candidemia. Eur J Clin Microbiol Infect Dis
2013;32:917e22.
17. Horvath LL, George BJ, Murray CK, Harrison LS, Hospenthal DR.
Direct comparison of the BACTEC 9240 and BacT/ALERT 3D
automated blood culture systems for Candida growth detec-
tion. J Clin Microbiol 2004;42:115e8.
18. Jamal W, Tamaray G, Pazhoor A, Rotimi VO. Comparative
evaluation of BacT/ALERT 3D and BACTEC systems for the re-
covery of pathogens causing bloodstream infections. Med Princ
Pract 2006;15:223e7.
19. Bassetti M, Righi E, Costa A, Fasce R, Molinari MP, Rosso R,
et al. Epidemiological trends in nosocomial candidemia in
intensive care. BMC Infect Dis 2006;6:21.
20. Davis SL, Vazquez JA, McKinnon PS. Epidemiology, risk factors,
and outcomes of Candida albicans versus non-albicans candi-
demia in nonneutropenic patients. Ann Pharmacother 2007;41:
568e73.
21. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treat-
ment of Candida bloodstream infection until positive blood
culture results are obtained: a potential risk factor for hospital
mortality. Antimicrob Agents Chemother 2005;49:3640e5.
22. Pfaller MA, Diekema DJ, Jones RN, Sader HS, Fluit AC,
Hollis RJ, et al. International surveillance of bloodstream in-
fections due to Candida species: frequency of occurrence and
in vitro susceptibilities to fluconazole, ravuconazole, and
430 L.-Y. Chen et al.voriconazole of isolates collected from 1997 through 1999 in
the SENTRY antimicrobial surveillance program. J Clin Micro-
biol 2001;39:3254e9.
23. Picazo JJ, Gonza´lez-Romo F, Candel FJ. Candidemia in the
critically ill patient. Int J Antimicrob Agents 2008;32:
S83e5.24. Swindell K, Lattif AA, Chandra J, Mukherjee PK, Ghannoum MA.
Parenteral lipid emulsion induces germination of Candida
albicans and increases biofilm formation on medical catheter
surfaces. J Infect Dis 2009;200:473e80.
25. Anderson JB. Evolution of antifungal-drug resistance: mecha-
nisms and pathogen fitness. Nat Rev Microbiol 2005;3:547e56.
